A survey of U.S. industry leaders published on June 21 found America holds advantages in commercialization, funding, and talent in biomedical science, but China has surpassed the United States in the number of clinical drug trials.
The survey, released on Monday at the Biotechnology Innovation Organization (BIO) meeting in San Diego, polled 117 senior figures from industry and academia.
Respondents saw China ahead in clinical development and supply chains. The two countries were viewed as roughly equal in scientific discovery, while the United States was seen as stronger in scaling production, attracting capital, and bringing medicines to market.
“The U.S. is still leading, but confidence is eroding,” Seema Kumar, chief executive of healthcare innovation group Cure, said. Most respondents viewed China as “an existential threat.”…